Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Go back to Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy| (NASDAQ: NRIX) | Delayed: 18.65 +1.10 (6.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.55 | 52 Week High | $ | |||
| Open | $17.83 | 52 Week Low | $ | |||
| Day High | $18.85 | P/E | N/A | |||
| Day Low | $17.83 | EPS | $ | |||
| Volume | 2,214,257 | |||||
